NASHVILLE, TN – Centerre Healthcare Corporation, a national provider of inpatient acute rehabilitation services, recently hired Douglas Johnson as senior vice president of development. Mr. Johnson will be responsible for all activities related to securing quality development partnerships with large Medical-Surgical hospital systems to bring acute medical rehabilitation programs to communities that promote the recovery of individuals who have functional deficits resulting from injury or illness.
Raven’s Discovery Platform in Cancer Stem Cell Biology Enhances MacroGenics’ Oncology Capabilities and Complements Proprietary Antibody Technology Platforms
ROCKVILLE, MD — MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the acquisition of Raven Biotechnologies, Inc., a privately held biotechnology company in South San Francisco, California, focused on the discovery and development of monoclonal antibody therapeutics for oncology through its cancer stem cell program.
Multi-Disciplinary Oversight Panel Includes American Brachytherapy Society, American Society of Breast Surgeons and American College of Radiation Oncology
SUNNYVALE, CA. – Xoft, Inc. today announced the launch and of the EXIBT Study (Electronic Xoft Intersociety BrachytherapyTrial), a national Electronic Brachytherapy patient registry under oversight from three national physician societies, the American Brachytherapy Society (ABS), the American Society of Breast Surgeons (ASBrS), and the American College of Radiation Oncology (ACRO).
SEATTLE, WA -— Calypso® Medical Technologies, Inc. announced today that Eric R. Meier, president and CEO, was named the Ernst & Young Entrepreneur Of The Year® 2008 Pacific Northwest award recipient in the Health Services and Life Sciences category. The award recognizes outstanding entrepreneurs who are building and leading dynamic and growing businesses. Meier was selected by an independent panel of judges and the award was presented at an Ernst & Young Entrepreneur Of The Year gala on June 13, 2008 in Seattle, WA.
SAN DIEGO, CA, — Patient enrollment into the GRAVITAS (Gauging Responsiveness With A VerifyNow® Assay-Impact On Thrombosis And Safety) trial has begun, officials from Accumetrics announced today. The GRAVITAS trial is designed to evaluate the use of the VerifyNow P2Y12 test to identify patients that exhibit a low response to antiplatelet therapy who are at risk for adverse cardiac events, and prove that these at-risk patients will benefit from tailored antiplatelet therapy.
Second Treatment Indication on Heels of Multi-Use Clearance for Axxent® System Strengthens the Creation of a New Platform in Radiation Therapy
SUNNYVALE, CA – Xoft, Inc., today announced that it has received clearance from the U.S. Food & Drug Administration (FDA) for applicators to be used with the Axxent® Electronic Brachytherapy System for the treatment of endometrial cancer.
SEATTLE, WA – Calypso® Medical announced today that the U.S. Food and Drug Administration (FDA) cleared a new indication for the use of implantable Beacon® electromagnetic transponders with the Calypso System in external beam radiation therapy.
ROCKVILLE, MD — MacroGenics Inc, a private biotechnology company focused on the development of products to treat autoimmune disorders, cancers, and infectious diseases, today announced the appointments of Dr. Jean-Christophe Tellier as Executive Vice President and Chief Commercial Officer and Mr. James Karrels as Vice President and Chief Financial Officer.
RESEARCH TRIANGLE PARK, NC — Tryton Medical, Inc. announced today that it has appointed J. Greg Davis as President and Chief Executive Officer. Founded in 2003, Tryton Medical is the leading developer of stents that are designed to definitively treat bifurcation lesions.
ST. LOUIS, MO – RiverVest Venture Partners announced today that it has completed fundraising for its second fund, RiverVest Venture Fund II, L.P., with total committed capital of $75 million from private investors. RiverVest’s first fund, which was licensed as a Small Business Investment Company, had total private capital of $45 million,plus one tier of leverage from the Small Business Administration.
NEWTON, MA – Tryton Medical, Inc., the leading developer of stents designed for the definitive treatment of bifurcation lesions announced today that it has closed a $14 million Series C round of financing.
DOVER, NH – TissueLink Medical, Inc., a privately held medical device company, announced today that the Company has changed its name to Salient Surgical Technologies, Inc. The name change is effective today.